SCHEMBL5989957

SCHEMBL5989957

CC(N)Cc1n[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.50
SLC6A4 P31645 2/20 0.50
SLC6A3 Q01959 2/20 0.50
HTR2A P28223 2/20 0.50
HTR2C P28335 2/20 0.50
ADRB1 P08588 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
HTR1E P28566 1/20 0.50
HTR7 P34969 1/20 0.50
HTR2B P41595 1/20 0.50
HTR6 P50406 1/20 0.50
KDM4E B2RXH2 6/20 0.48
GAA P10253 2/20 0.48
PDPK1 O15530 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30166149 1.00 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3HTR2AHTR2C
SCHEMBL9963337 0.86 KDM4E (0.47) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL2268086 0.79 KDM4E (0.44) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL2268143 0.79 KDM4E (0.44) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL2268137 0.79 KDM4E (0.44) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL9727950 0.79 KDM4E (0.44) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL2268091 0.79 KDM4E (0.44) KDM4EGAAPDPK1CYP3A4CYP1A2
SCHEMBL905990 0.78 PDPK1 (0.54) HTR2AHTR2CHTR1AHTR1DHTR1B
SCHEMBL2553028 0.78 HTR2C (0.48) SLC6A2HTR2AHTR2CHTR1AHTR1D
SCHEMBL5987890 0.78 HTR2A (0.55) SLC6A2SLC6A4HTR2AHTR2CHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052431-A1 5-Hydroxy indazole derivatives for treating glaucoma MAY JESSE A 2006-03-09 US disclosed
US-7005443-B1 5-Hydroxy indazole derivatives for treating glaucoma ALCON, INC. (CH) 2006-02-28 US disclosed
CN-1450995-A 5-hydroxy indazole derivatives for treating glaucoma ALCON AG (CH) 2003-10-22 CN disclosed
EP-1268439-A1 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA Alcon Inc. (CH) 2003-01-02 EP disclosed
WO-2001070701-A1 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA ALCON, INC. (CH) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052431-A1 5-Hydroxy indazole derivatives for treating glaucoma PTGIS, PTGIR, PDE3A SLC6A2 3544/4885SLC6A4 2369/4885SLC6A3 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.